Hamilton Lane Inc. $HLNE Shares Acquired by Copeland Capital Management LLC

Key Points

• Copeland Capital Management LLC boosted its stake in Hamilton Lane by 5.9% in Q4 to 524,166 shares (about $70.4M), making HLNE its 12th-largest holding and representing roughly 0.94% ownership; institutional investors own 97.4% of the stock.
• Hamilton Lane delivered an earnings beat with $1.55 EPS vs $1.28 expected and revenue of $198.6M (+18% YoY), pays a $0.54 quarterly dividend (annual $2.16, 2.1% yield), and trades near $103 with a $5.75B market cap and a consensus "Moderate Buy" target of $155.38.

Copeland Capital Management LLC boosted its stake in shares of Hamilton Lane Inc. (NASDAQ:HLNE - Free Report) by 5.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 524,166 shares of the company's stock after purchasing an additional 28,981 shares during the quarter. Hamilton Lane makes up approximately 1.6% of Copeland Capital Management LLC's holdings, making the stock its 12th largest position. Copeland Capital Management LLC owned approximately 0.94% of Hamilton Lane worth $70,401,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HLNE. Royal Bank of Canada boosted its position in Hamilton Lane by 6.0% during the 1st quarter. Royal Bank of Canada now owns 52,466 shares of the company's stock valued at $7,800,000 after purchasing an additional 2,948 shares during the period. Jones Financial Companies Lllp boosted its position in Hamilton Lane by 4,806.7% during the 1st quarter. Jones Financial Companies Lllp now owns 5,103 shares of the company's stock valued at $759,000 after purchasing an additional 4,999 shares during the period. Geneos Wealth Management Inc. boosted its position in Hamilton Lane by 196.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 383 shares of the company's stock valued at $57,000 after purchasing an additional 254 shares during the period. First Trust Advisors LP boosted its position in Hamilton Lane by 26.7% during the 2nd quarter. First Trust Advisors LP now owns 31,483 shares of the company's stock valued at $4,474,000 after purchasing an additional 6,636 shares during the period. Finally, Amundi boosted its position in Hamilton Lane by 39,766.7% during the 2nd quarter. Amundi now owns 2,392 shares of the company's stock valued at $347,000 after purchasing an additional 2,386 shares during the period. Institutional investors and hedge funds own 97.40% of the company's stock.

Hamilton Lane Stock Down 2.7%

HLNE opened at $103.16 on Friday. Hamilton Lane Inc. has a one year low of $90.47 and a one year high of $179.19. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.27 and a current ratio of 3.27. The stock's fifty day moving average is $103.23 and its 200-day moving average is $121.71. The company has a market capitalization of $5.75 billion, a PE ratio of 18.52 and a beta of 1.33.

Hamilton Lane (NASDAQ:HLNE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.27. Hamilton Lane had a return on equity of 27.82% and a net margin of 30.59%.The company had revenue of $198.59 million for the quarter, compared to the consensus estimate of $195.36 million. During the same quarter in the previous year, the business earned $1.25 EPS. The company's quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities analysts predict that Hamilton Lane Inc. will post 6.2 EPS for the current fiscal year.

Hamilton Lane Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 6th. Stockholders of record on Friday, March 20th were paid a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Friday, March 20th. Hamilton Lane's payout ratio is currently 38.78%.

Analyst Ratings Changes

HLNE has been the subject of a number of analyst reports. UBS Group reduced their price objective on Hamilton Lane from $184.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 20th. Keefe, Bruyette & Woods boosted their price target on Hamilton Lane from $161.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, January 8th. Oppenheimer reduced their price target on Hamilton Lane from $230.00 to $171.00 and set an "outperform" rating for the company in a research report on Monday, April 13th. Morgan Stanley reduced their price target on Hamilton Lane from $159.00 to $141.00 and set an "equal weight" rating for the company in a research report on Tuesday. Finally, Zacks Research lowered Hamilton Lane from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $155.38.

Hamilton Lane Company Profile

Hamilton Lane is a global private markets investment management firm specializing in the full spectrum of private equity and credit strategies. The company partners with institutional investors and wealth managers to design, implement and manage customized portfolios in primary fund investing, secondary market transactions and direct co-investment opportunities. By combining investment selection, portfolio construction and ongoing monitoring, Hamilton Lane seeks to optimize risk-adjusted returns across diverse private markets exposures.

Founded in 1991, Hamilton Lane has developed a track record of investment and advisory services in private markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.